Evidence map›Paper›PMID 37036471›Full record

ArticleAging2023

Machine learning-based construction of immunogenic cell death-related score for improving prognosis and response to immunotherapy in melanoma.

Guoyin Li, Huina Zhang, Jin Zhao, Qiongwen Liu, Jinke Jiao, Mingsheng Yang, Changjing Wu

Abstract read
In one paragraph

Article in Aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. DamageZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guoyin LiCollege of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, Henan, China.
Huina ZhangCollege of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, Henan, China.
Jin ZhaoCollege of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, Henan, China.
Qiongwen LiuCollege of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, Henan, China.
Jinke JiaoCollege of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, Henan, China.
Mingsheng YangCollege of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, Henan, China.
Changjing WuCollege of Life Science and Agronomy, Zhoukou Normal University, Zhoukou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunogenic cell death (ICD) is a form of regulated cell death (RCD) which could drive the activation of the innate and adaptive immune responses. In this work, we aimed to develop an ICD-related signature to facilitate the assessment of prognosis and immunotherapy response for melanoma patients.

methodsA set of machine learning methods, including consensus clustering, non-negative matrix factorization (NMF) method and least absolute shrinkage and selection operator (LASSO) logistic regression model, and bioinformatics analytic tools were integrated to construct an ICD-related risk score (ICDscore). CIBERSORT and ESTIMATE algorithm were used to evaluate the infiltration of immune cells. The 'pRRophetic' package in R and 6 cohorts of melanoma patients receiving immunotherapy were used for therapy sensitivity analyses. The predictive performance between ICDscore with other mRNA signatures were also compared.

resultsThe ICDscore could predict prognosis and immunotherapy response in multiple cohorts, and displayed superior performance than other forms of cell death-related signatures or 52 published signatures. The melanoma patients with low ICDscore were marked with high infiltration of immune cells, high expression of immune checkpoint inhibitor-related genes, and increased tumor mutation burden.

conclusionsIn conclusion, we constructed a stable and robust ICD-related signature for evaluating the prognosis and benefits of immunotherapy, and it could serve as a promising tool to guide decision-making and surveillance for individual melanoma patients.

Indexed as

Immunogenic Cell DeathMelanomaHumansImmunotherapyMachine LearningPrognosisTumor Microenvironmentimmunogenic cell deathimmunotherapymachine learningmelanomaprognostic model

Identifiers

PMID37036471
PMCPMC10120887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.